Investigational Drug Information for MGB-BP-3
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for MGB-BP-3?
MGB-BP-3 is an investigational drug.
There have been 5 clinical trials for MGB-BP-3.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 15th 2019.
The most common disease conditions in clinical trials are Vomiting, Non-alcoholic Fatty Liver Disease, and Postoperative Nausea and Vomiting. The leading clinical trial sponsors are MGB Biopharma Limited, Synlab Services, and Viapath.
There are two US patents protecting this investigational drug and twenty international patents.
Summary for MGB-BP-3
| US Patents | 2 |
| International Patents | 20 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2019-01-15) |
| Vendors | 9 |
Recent Clinical Trials for MGB-BP-3
| Title | Sponsor | Phase |
|---|---|---|
| Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD | Syneos Health | Phase 2 |
| Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD | MGB Biopharma Limited | Phase 2 |
| MR Antagonist and STRIATIN | Brigham and Women's Hospital | Phase 4 |
Clinical Trial Summary for MGB-BP-3
Top disease conditions for MGB-BP-3
Top clinical trial sponsors for MGB-BP-3
US Patents for MGB-BP-3
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| MGB-BP-3 | See Plans and Pricing | Halogenated salicylanilides for treating clostridium infections | UNION therapeutics A/S (Hellerup, DK) | See Plans and Pricing |
| MGB-BP-3 | See Plans and Pricing | Minor groove binders | University of Strathclyde (Glasgow, GB) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for MGB-BP-3
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| MGB-BP-3 | China | CN107847507 | 2035-05-29 | See Plans and Pricing |
| MGB-BP-3 | China | CN113368116 | 2035-05-29 | See Plans and Pricing |
| MGB-BP-3 | European Patent Office | EP3302492 | 2035-05-29 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
